NRx Pharmaceuticals, Inc. (NRXP) shares are rising more than 7 percent on Monday morning after the company announced that Zyesami or aviptadil phase 2b/3 clinical trial demonstrated relief from respiratory distress in critical COVID-19 patients.
The company said the additional finding showed an improvement in blood oxygen, indicative of improved lung function, within a day of starting treatment. Further, the company noted that the average difference in Respiratory Distress Ratio between those treated with aviptadil and placebo was both clinically meaningful and statistically significant.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com